Targeting antibodies for the treatment of aggressive cancer

Targinta develops targeting and toxin-armed antibodies for aggressive cancer. The company was founded based on the discovery of a unique and patent-protected target molecule, integrin α10β1, and the aim is to improve the treatment of cancer, with a focus invasive, hard-to treat cancer forms such as triple-negative breast cancer and the brain cancer glioblastoma.